Skip to main content

Publisher Correction to: Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole

The Original Article was published on 03 February 2021

Publisher Correction to: J Transl Med (2021) 19: 50 https://doi.org/10.1186/s12967-021-02721-9

During the publication process an error was introduced in the original publication of this article [1].

In Table 1 the value for “Concurrent antidepressant use” was accidentally changed. In this correction article the incorrect and correct values are published for clarification. The full table is available via the original article. The publisher apologizes to the readers and authors for the inconvenience. The original article has been updated.

Incorrect

Demographics

Responders

Concurrent antidepressant use

46,175 (61.3%)*

  1. *p = 0.145

Correct

Demographics

Responders

Concurrent antidepressant use

46/75 (61.3%)

  1. *p = 0.145

Reference

  1. Crosby LD, Kalanidhi S, Bonilla A, Subramanian A, Ballon JS, Bonilla H. Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole. J Transl Med. 2021;19:50. https://doi.org/10.1186/s12967-021-02721-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Consortia

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Journal of Translational Medicine. Publisher Correction to: Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole. J Transl Med 19, 217 (2021). https://doi.org/10.1186/s12967-021-02875-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12967-021-02875-6